A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
- To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly
(QW) and twice daily-once weekly (BID-QW).
- To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007
monotherapy administered BID-QW.
- To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy.
- To determine the optimal dose and schedule of ERAS-007 monotherapy.
- To evaluate antitumor activity of ERAS-007 in various solid tumors.